Related references
Note: Only part of the references are listed.High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma
Jianjun Xu et al.
CANCER CELL INTERNATIONAL (2022)
HJURP regulates cell proliferation and chemo-resistance via YAP1/NDRG1 transcriptional axis in triple-negative breast cancer
Misha Mao et al.
CELL DEATH & DISEASE (2022)
Tumor Derived Extracellular Vesicles Drive T Cell Exhaustion in Tumor Microenvironment through Sphingosine Mediated Signaling and Impacting Immunotherapy Outcomes in Ovarian Cancer
Prachi Gupta et al.
ADVANCED SCIENCE (2022)
HJURP is a prognostic biomarker for clear cell renal cell carcinoma and is linked to immune infiltration
Fan Zhang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape
Yoshiko Takeuchi et al.
SCIENCE IMMUNOLOGY (2021)
Hypomethylation-driven overexpression of HJURP promotes progression of hepatocellular carcinoma and is associated with poor prognosis
Ye Li et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy
Stephen L. Shiao et al.
CANCER CELL (2021)
Integrated analysis of multimodal single-cell data
Yuhan Hao et al.
CELL (2021)
HJURP promotes proliferation in prostate cancer cells through increasing CDKN1A degradation via the GSK3β/JNK signaling pathway
Wenjie Lai et al.
CELL DEATH & DISEASE (2021)
IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures
Dongqiang Zeng et al.
FRONTIERS IN IMMUNOLOGY (2021)
clusterProfiler 4.0: A universal enrichment tool for interpreting omics data
Tianzhi Wu et al.
INNOVATION (2021)
Holliday junction recognition protein promotes pancreatic cancer growth and metastasis via modulation of the MDM2/p53 signaling
Chen-jing Wang et al.
CELL DEATH & DISEASE (2020)
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
Gaia Giannone et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma
Gaurav Sharma et al.
JCI INSIGHT (2020)
Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma
Ankur Sharma et al.
CELL (2020)
Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer
Cheng Luo et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
Qi Peng et al.
NATURE COMMUNICATIONS (2020)
Prognostic Relevance of HJURP Expression in Patients with Surgically Resected Colorectal Cancer
Dong Hyun Kang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma
Yaojie Fu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Pro-Survival Lipid Sphingosine-1-Phosphate Metabolically Programs T Cells to Limit Anti-tumor Activity
Paramita Chakraborty et al.
CELL REPORTS (2019)
MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
Douglas D. Fang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
HJURP Promotes Epithelial-to-Mesenchymal Transition via Upregulating SPHK1 in Hepatocellular Carcinoma
Tianchi Chen et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2019)
A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy
Masahiro Shibata et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
HJURP promotes hepatocellular carcinoma proliferation by destabilizing p21 via the MAPK/ERK1/2 and AKT/GSK3β signaling pathways
Tianchi Chen et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Inheritance of CENP-A Nucleosomes during DNA Replication Requires HJURP
Ewelina Zasadzinska et al.
DEVELOPMENTAL CELL (2018)
Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma
Hyung-Don Kim et al.
GASTROENTEROLOGY (2018)
Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance
Donnele Daley et al.
NATURE MEDICINE (2017)
A Non-Synonymous Single Nucleotide Polymorphism in the HJURP Gene Associated with Susceptibility to Hepatocellular Carcinoma among Chinese
Wenfeng Huang et al.
PLOS ONE (2016)
PML control of cytokine signaling
Ghizlane Maarifi et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2014)
HJURP Regulates Cellular Senescence in Human Fibroblasts and Endothelial Cells Via a p53-Dependent Pathway
Jong-Ik Heo et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2013)
HJURP binds CENP-A via a highly conserved N-terminal domain and mediates its deposition at centromeres
Muhammad Shuaib et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer
Zhi Hu et al.
BREAST CANCER RESEARCH (2010)
HJURP Is a Cell-Cycle-Dependent Maintenance and Deposition Factor of CENP-A at Centromeres
Elaine M. Dunleavy et al.
CELL (2009)
Centromere-Specific Assembly of CENP-A Nucleosomes Is Mediated by HJURP
Daniel R. Foltz et al.
CELL (2009)
WGCNA: an R package for weighted correlation network analysis
Peter Langfelder et al.
BMC BIOINFORMATICS (2008)
Cytoscape: A software environment for integrated models of biomolecular interaction networks
P Shannon et al.
GENOME RESEARCH (2003)